Sibutramine-induced mania as the first manifestation of bipolar disorder

BMC Psychiatry

Krzysztof Zwierz⁵  Jerzy Robert Ładny¹  Agata Szulc²  Anna Zalewska³  Katarzyna Simonienko²  Sławomir Dariusz Szajda¹  Beata Zalewska-Szajda⁴  Napoleon Waszkiewicz² 

[1] Department of Emergency Medicine and Disasters, Medical University of Białystok, Białystok, Poland;Department of Psychiatry, Medical University of Białystok, 16-070,, Choroszcz, Poland;Department of Paedodontics, Medical University of Białystok, Białystok, Poland;Department of Imaging Diagnostics, Medical University of Białystok, Children Hospital, Białystok, Poland;Medical College of the Universal Education Society, Łomża, Poland

关键词: Bipolar disorder;    Mania;    Sibutramine;    Obesity;   

Others  :  1124388
DOI  :  10.1186/1471-244X-12-43

 received in 2012-01-14, accepted in 2012-05-18,  发布年份 2012

【 摘 要 】

Background

Sibutramine, used in obesity treatment, has been associated with many neuropsychiatric side effects including hypomanic and manic episodes. Hypomanic/manic episodes related to sibutramine treatment were earlier reported in patients who had previous history of bipolar disorder, after sibutramine overdose, after over-the-counter product illegally containing very high dose of sibutramine, together with psychotic symptoms, in organic patient, or after interaction of sibutramine with other drugs.

Case presentation

We report the first case of a patient with clear manic episode, after treatment with recommended dose of sibutramine, without previous history of mood disorders, organic changes or drug interactions, that was followed by episode of depression.

Conclusion

Minimal recommended dose of sibutramine induced manic episode that was the first manifestation of bipolar disorder. The manic episode, associated with sibutramine treatment, was induced in a person without previous history of mood disorders. Potential risks associated with the treatment of obesity using sibutramine warn physicians to be alert not only to common and cardiovascular but also to psychiatric adverse effects. A careful assessment of patient’s mental state and detailed psychiatric family history should be done before sibutramine treatment. In patients with a family history for bipolar disorder the use of even minimal dose of sibutramine should be contraindicated.

【 授权许可】

   
2012 Waszkiewicz et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Florentin M, Liberopoulos EN, Elisaf MS: Sibutramine-associated adverse effects: a practical guide for its safe use. Obes Rev 2008, 9:378-387.
• [2]Nathan PJ, O'Neill BV, Napolitano A, Bullmore ET: Neuropsychiatric adverse effects of centrally acting antiobesity drugs. CNS Neurosci Ther 2011, 5:490-505.
• [3]Padwal RS, Majumdar SR: Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007, 369:71-77.
• [4]Lee J, Teoh T, Lee TS: Catatonia and psychosis associated with sibutramine: A case report and pathophysiologic correlation. J Psychosom Res 2008, 64:107-109.
• [5]Taliński T, Chojnacka J: Sibutramine-associated psychotic episode. Am J Psych 2000, 157:2057-2058.
• [6]Dogangun B, Bolat N, Rustamov I, Kayaalp L: Sibutramine-induced psychotic episode in an adolescent. J Psychosom Res 2008, 65:505-506.
• [7]Figueroa CRA, Castaño CC: Sibutramine associated psychotic episode: a case report. Rev Med Chil 2008, 136:671-673.
• [8]Naik S, Khoo CL, Lua R, Chai SB, Liew A, Sim K: Recurrent episodes of brief affective psychosis induced by sibutramine. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:1359-1360.
• [9]Müller D, Weinmann W, Hermanns-Clausen M: Chinese slimming capsules containing sibutramine sold over the Internet: a case series. Dtsch Arztebl Int 2009, 106:218-222.
• [10]Fiorentini S, Russo D, D'Amato A, Limpido L, Bersani G: Sibutramine-related panic attack: a clinical case of apparent resolution with paroxetine. Riv Psichiatr 2009, 44:64-67.
• [11]Fernandez P, Peiro AM: A sibutramine-induced delusional disorder relapse. J Neuropsychiatry Clin Neurosci 2007, 19:88-89.
• [12]Fu PK, Hsu HY, Wang PY: Transient global amnesia after taking sibutramine: a case report. Neurologist 2010, 16:129-131.
• [13]Rocha FF, Bamberg TO, Pinto FC, Gomes LM, Silveira S: Hypomanic episode secondary to sibutramine in a patient with type-I bipolar disorder. Rev Bras Psiquiatr 2008, 30:400-401.
• [14]Cordeiro Q, Vallada H: Sibutramine-induced mania episode in a bipolar patient. Int J Neuropsychopharmacol 2002, 5:283-284.
• [15]Benazzi F: Organic hypomania secondary to sibutramine-citalopram interaction. J Clin Psychiatry 2002, 63:165.
• [16]Eker MC, Onat O, Pirildar S, Ozaskinli S: Case report: A mixed episode induced by Sibutramine. Klin Psikofarmacol Bul 2003, 13:129-132.
• [17]Binbay T: First-episode mania with psychotic features induced by over-the-counter diet aids containing sibutramine. Turk Psikiyatri Derg 2010, 4:335-337.
• [18]Goldberg JF, Truman CJ: Antidepressant-induced mania: an overview of current controversies. Bipolar Disord 2003, 5:407-420.
• [19]Daray FM, Thommi SB, Ghaemi SN: The pharmacogenetics of antidepressant-induced mania: a systematic review and meta-analysis. Bipolar Disord 2010, 12:702-706.
• [20]Waszkiewicz N, Szulc A: An intellectual construct of bipolarity diagnosis. http://www.bmj.com/rapid-response/2011/11/03/intellectual-construct-bipolarity-diagnosis webcite
• [21]Ferreira AdA, Neves FS, da Rocha FF, Silva GSe, Romano-Silva MA, Miranda DM, De Marco L, Correa H: The role of 5-HTTLPR polymorphism in antidepressant-associated mania in bipolar disorder. J Affect Disord 2009, 112:267-272.
• [22]McElroy SL, Frye MA, Altshuler LL, Suppes T, Hellemann G, Black D, Mintz J, Kupka R, Nolen W, Leverich GS, Denicoff KD, Post RM, Keck PE: A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. Bipolar Disord 2007, 9:426-434.
• [23]European Medicines Agency: Press release 21 January. http://www.ema.europa.eu/pdfs/human/referral/sibutramine/3940810en.pdf webcite